You are here

  • Home
  • Archive
  • Volume 9, Issue 7
  • First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): primary and biomarker analyses of a phase II study

Article metrics

Article menu
XML
Clinical/translational cancer immunotherapy
Original research
First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): primary and biomarker analyses of a phase II study

 

Online download statistics by month:

Online download statistics by month: July 2021 to March 2024

AbstractFullPdf
Jul 2021388388192
Aug 2021321321166
Sep 202120720782
Oct 202118818886
Nov 202118018082
Dec 202115515546
Jan 202214915351
Feb 20229810558
Mar 202215416798
Apr 202214515672
May 202213514693
Jun 202210411454
Jul 2022107116111
Aug 202214815174
Sep 202219520491
Oct 202217823286
Nov 2022245248101
Dec 202215115237
Jan 202316816864
Feb 202320420473
Mar 2023242242104
Apr 2023170173112
May 202317818183
Jun 202321722165
Jul 202319119462
Aug 202318318566
Sep 202317617772
Oct 202317617673
Nov 202320720973
Dec 202320821054
Jan 202413413575
Feb 202414114261
Mar 2024188198127
Total603161982744